Patrick Schöffski, KU Leuven, Leuven, Belgium discusses BI 907828, a highly potent mouse double minute-2 (MDM2) – p53 antagonist, in a Phase I dose-escalation clinical study in patients with solid tumors (NCT03449381). BI 907828 has demonstrated preclinical antitumor activity in vivo, especially in TP53 wild-type models. Dr Schoffski explains the rationale behind this study, which is to determine the most suitable dose of BI 907828 that patients are able to tolerate. The drug is administered orally and doses are taken on one day every 3 weeks or on two days every 4 weeks. BI 907828 exerts its action by blocking the interaction between MDM2 and p53, by binding to free MDM2. p53 remains inactivated and this restores function in tumors with wild-type p53. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
